The presence of BCSCs is also an important cause of ET resistance in luminal breast cancer [72,73], which can be regulated by the cyclin-dependent kinase 4/6 (CDK4/6) complex [74,75] and mechanistic target of rapamycin (mTOR) signaling [76]. Here, MTOR is linked to breast carcinoma.